A supported liquid extraction LC–MS/MS method for determination of concentrations of GDC‐0425, a small molecule Checkpoint kinase 1 inhibitor, in human plasma. (5th July 2016)

• Record Type: Journal Article
• Authors: Ding, Xiao; Chen, Yuan; Sahasranaman, Srikumar; Shi, Yifan; McKnight, Janine; Dean, Brian
• Is Part Of: Biomedical chromatography. Volume 30:Number 12(2016:Dec.)
• Page Start: 1984
• Page End: 1991
• Publication Date: 2016-07-05
• Subjects: checkpoint kinase 1 (ChK1) -- GDC‐0425 -- human plasma -- LC–MS/MS -- supported liquid extraction; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.3775
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: A liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for the determination of GDC‐0425 concentrations in human plasma has been developed and validated. Supported liquid extraction was used to extract plasma samples (50 μL) and the resulting samples were analyzed using reverse‐phase chromatography and mass spectrometry coupled with a turbo‐ionspray interface. The mass analysis of GDC‐0425 was performed using multiple reaction monitoring transitions in positive ionization mode. The method was validated over the calibration curve range of 1.00–1000 ng/mL using linear regression and 1/ x 2 weighting. Within‐run relative standard deviation ranged from 0.8 to 5.1%, while between‐run RSD varied from 1.9 to 4.7% for QCs. The accuracy ranged from 90.0 to 101.0% of nominal for within‐run and from 94.0 to 100.0% of nominal for between‐run. Overall extraction recovery was 87.4% for GDC‐0425 and 87.9% for GDC‐0425‐d9 . Stability of GDC‐0425 was established in human plasma for 374 days at −20 and −70 °C and established in reconstituted sample extracts for 88 h when stored at 2–8 °C. Stable‐labeled internal standard was used to minimize matrix effects. This assay was used to characterize the pharmacokinetics of GDC‐0425 in cancer patients.